• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

[68Ga]Ga-PSMA-11 PET/CT shows value in initial staging of prostate cancer

News
Article

Patients with high-risk disease were shown to have a significantly higher mean value of SUVmax compared with patients with low-risk disease (23.5 ± 13.2 vs 10.6 ± 5.4; P < 0.05).

Data from a study recently published in Nuclear Medicine in Central and Eastern Europe showed a correlation between SUVmax values derived from [68Ga]GA-PSMA-11 PET/CT scans and WHO/ISUP (World Health Organization/International Society of Urological Pathology) tumor grade group, suggesting that [68Ga]GA-PSMA-11 may be a useful tool in the initial staging of prostate cancer.1

“SUVmax values of intermediate and high-risk patients were significantly higher than those of low-risk patients, supporting the usage of [68Ga]GA-PSMA-11 PET/CT in the initial staging of prostate cancer," concluded the authors.

“SUVmax values of intermediate and high-risk patients were significantly higher than those of low-risk patients, supporting the usage of [68Ga]GA-PSMA-11 PET/CT in the initial staging of prostate cancer," concluded the authors.

For the study, investigators retrospectively assessed 34 patients who underwent [68Ga]GA-PSMA-11 PET/CT for initial staging of prostate cancer. All patients included in the analysis had prostate cancer confirmed by histological assessment after biopsy and had Gleason score and PSA serum values obtained.

Overall, data from the study showed that 55.9% patients (n = 19) had extended disease detected by [68Ga]GA-PSMA-11 PET/CT. Further, 34.4% of patients (n = 12) had infiltration of seminal vesicles, 32.4% of patients (n = 11) had metastases in the lymph nodes, and 20.6% of patients (n = 7) had bone metastases.

The investigators also observed a positive correlation between SUVmax values and WHO/ISUP group (Pearson's r = 0.557; P < .01), as well as between SUVmax values and PSA values (Pearson's r = 0.34; P < .05). No significant correlation was found between WHO/ISUP groups and PSA values (Pearson's r = 0.26).

Additionally, patients with high-risk disease (WHO/ISUP groups 3-5) were shown to have a significantly higher mean value of SUVmax compared with patients with low-risk disease (WHO/ISUP groups 1-2), with a mean value of 23.5 ± 13.2 for intermediate to high-risk disease vs 10.6 ± 5.4 for low-risk (P < 0.05). Broken up by individual grade groups, the mean SUVmax was 6.3 ± 1.8 for patients in WHO/ISUP group 1, 12.8 ± 5.3 in grade group 2, 19.3 ± 8.7 in grade group 3, 29.9 ± 16.9 in grade group 4, and 29.2 ± 15 in grade group 5.

On this finding, the authors note,1 “The correlation between the Gleason score and SUVmax value can be explained by the increased intensity of PSMA expression as the tumor grade increases.”

In total, the study included 34 patients who underwent a [68Ga]GA-PSMA-11 PET/CT scan between April 2021 and January 2023 at the Department of Nuclear Medicine at the University Hospital Centre Zagreb in Croatia. The mean age of participants was 69.7 ± 9.8 years. The mean PSA value was 33.8 ± 40.9 nmol/L (range, 2.2-232) among all patients in the study, and the mean SUVmax in prostate lesions was 19.5 ± 12.6.

In the study, 4 patients had WHO/ISUP grade group 1 (Gleason 3 + 3), 8 patients had grade group 2 (Gleason 4 + 3), 13 patients had grade group 3 (Gleason 4 + 3), 4 patients had grade group 4 (Gleason 4 + 4), and 4 patients had grade group 5 (Gleason 9 and 10).

Overall, the authors concluded,1 “SUVmax values of intermediate and high-risk patients were significantly higher than those of low-risk patients, supporting the usage of [68Ga]GA-PSMA-11 PET/CT in the initial staging of prostate cancer.”

Reference

1. Rogic I, Golubic AT, Zuvic M, et al. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values. Nucl Med Rev Cent East Eur. 2024;27(0):6-12. doi:10.5603/nmr.97424

Related Videos
David I. Lee, MD, FACS, answers a question during a video interview
Todd M. Morgan, MD, answers a question during a Zoom video interview
Man talking with doctor | Image Credit: © rocketclips - stock.adobe.com
Prostate cancer cell division | Image Credit: © PRB ARTS - stock.adobe.com
Group of doctors reading a document | Image Credit: © Flamingo Images - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.